EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Maternity versus non-maternity healthcare settings for the diagnosis of gestational diabetes or diabetes in pregnancy

Nora Cryns, Julia Schroer, Anna H Noel-Storr, Juan Va Franco, Shayesteh Jahanfar, Sarah Messer, Ana-Mihaela Zorger, Ünsal Çolakkeskin, Suci Ardini Widyaningsih, Edward Mullins, Karen D Gibbs, Nicole Skoetz und 1 weitere

Cochrane Database of Systematic Reviews · 29.10.2026 · 2026 (10)

DOI: 10.1002/14651858.cd016295 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cochrane Database of Systematic Reviews, online erschienen am 29.10.2026. Verfasst von Nora Cryns und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cochrane Evidence Synthesis Unit Germany/UK, Institute of Public Health, Faculty of Medicine and University Hospital Cologne, University of Cologne, …. Hauptthemen laut MEDLINE: Diabetes, Gestational, Maternal Health Services. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE: Substantial uncertainty exists regarding how healthcare system factors, especially care setting types, affect the uptake and implementation of gestational diabetes or diabetes in pregnancy screening in practice. Evidence suggests that the care environment may influence diagnostic processes. OBJECTIVES: To assess the effectiveness of maternity and non-maternity healthcare settings for the diagnosis of gestational diabetes mellitus or diabetes in pregnancy. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) for randomised controlled trials (RCTs) up to April 2026, and for controlled non-randomised studies of interventions (NRSIs) up to December 2025. We also searched CENTRAL to identify ongoing trials. ELIGIBILITY CRITERIA: We included RCTs and planned to include cluster-RCTs and NRSIs, but we did not find any. Eligible participants were pregnant women being screened for gestational diabetes mellitus (GDM) or diabetes in pregnancy. We defined maternity healthcare settings as those specialising in care for pregnant, birthing, and postpartum individuals, with appropriate screening protocols, and non-maternity healthcare settings as general medical environments lacking a focus on pregnancy and women's care. We considered any screening format (e.g. risk-factor-based screening) and any diagnostic test (e.g. one- and two-step oral glucose tolerance tests (OGTT)). OUTCOMES: Critical health service outcomes were compliance with screening and follow-up guidelines, diagnosis of gestational diabetes or diabetes in pregnancy, maternal emergency department visits during pregnancy, maternal antenatal hospitalisation, length of maternal hospitalisation, length of neonatal hospitalisation, and care accessibility. Critical maternal outcomes included hypertensive disorders, maternal death, intensive care admissions, hyperglycaemia requiring pharmacological treatment, infections, and postpartum glucose intolerance, including progression to diabetes, within 15 years after birth. Critical child-related outcomes encompassed perinatal death, neonatal intensive care admissions, preterm birth, neonatal hypoglycaemia, large-for-gestational-age, shoulder dystocia, and birth trauma. Further critical and important outcomes not included in the summary of findings tables can be found in the full text. RISK OF BIAS: We used the Cochrane RoB 2 tool to assess bias in the RCTs. We had planned to use ROBINS-I version 2 to assess bias in the NRSIs if we had identified any. SYNTHESIS METHODS: We used standard Cochrane methodology. We planned to synthesise results for each outcome using meta-analysis where possible (inverse-variance or Mantel-Haenszel approaches; fixed-effect model). We used GRADE to assess the certainty of the evidence for each outcome. INCLUDED STUDIES: We included one RCT with 781 participants: 390 were randomised to screening in a maternity healthcare setting and 391 were randomised to screening in a non-maternity healthcare setting. Except for screening compliance, trialists evaluated all outcomes using a per-protocol analysis instead of by original randomised groups. This approach created substantial disparities in sample sizes between settings and largely nullified the methodological protections typically provided by a randomised design. The trial evaluated screening for GDM only. We did not identify any ongoing studies or studies awaiting classification. SYNTHESIS OF RESULTS: Health service outcomes Screening in a maternity healthcare setting may increase compliance with screening and follow-up guidelines (risk ratio (RR) 1.69, 95% confidence interval (CI) 1.53 to 1.87; 781 participants) and may improve care accessibility, assessed as time to access antenatal diabetes care, measured in days (mean difference (MD) -4.70, 95% CI -6.03 to -3.37; 690 participants), both with low-certainty evidence. We are very uncertain about the effect of screening in a maternity healthcare setting versus a non-maternity healthcare setting on diagnosis of gestational diabetes or diabetes in pregnancy (RR 1.10, 95% CI 0.60 to 2.01; 690 participants; very low-certainty evidence) and length of neonatal hospitalisation (MD 0.04, 95% CI -0.57 to 0.65; 690 participants; very low-certainty evidence). No direct evidence was available on screening for diabetes in pregnancy as distinct from GDM. No data were reported on maternal emergency department visits, maternal antenatal hospitalisation, length of maternal hospitalisations, and costs. Maternal outcomes We are very uncertain about the effect of screening in a maternity healthcare setting versus a non-maternity healthcare setting on pre-eclampsia (RR 1.24, 95% CI 0.56 to 2.75; 690 participants; very low-certainty evidence). The following outcomes were not reported: eclampsia, HELLP syndrome, maternal death, admission to intensive care, hyperglycaemia requiring pharmacological treatment, infections, and postpartum glucose intolerance. Child-related outcomes We are very uncertain about the effect of screening in a maternity healthcare setting versus a non-maternity healthcare setting on: stillbirth or foetal death (RR 0.91, 95% CI 0.08 to 9.93), admission to neonatal intensive care (RR 1.01, 95% CI 0.59 to 1.71), preterm birth (RR 1.06, 95% CI 0.41 to 2.71), neonatal hypoglycaemia (RR 0.91, 95% CI 0.23 to 3.59), large-for-gestational-age (RR 0.73, 95% CI 0.51 to 1.04), shoulder dystocia (RR 0.15, 95% CI 0.01 to 3.70), and birth trauma (RR 0.91, 95% CI 0.08 to 9.93), all with 690 participants each and very low-certainty evidence. An effect estimate for neonatal death was not estimable (maternity setting: 0/475; non-maternity setting: 0/215). AUTHORS' CONCLUSIONS: There is insufficient evidence to determine whether screening for gestational diabetes or diabetes in pregnancy in maternity healthcare settings compared with non-maternity healthcare settings improves health service, maternal, or child-related outcomes. Low-certainty evidence from a single study indicates that screening in maternity healthcare settings may result in a reduction in time to access antenatal diabetes care and may increase compliance. The effects on other outcomes remain unknown. Conducting studies using intention-to-treat analyses could bridge existing research gaps, enhancing effect estimates and certainty. FUNDING: This Cochrane review was funded by the World Health Organization (WHO) and the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). REGISTRATION: Protocol available via PROSPERO: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251108692.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes, GestationalMaternal Health ServicesHumansFemalePregnancyRandomized Controlled Trials as Topic

Autor:innen und Institutionen

  • Cochrane Evidence Synthesis Unit Germany/UK, Institute of Public Health, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Publishing and Technology Directorate, Cochrane Central Executive Team, London, UK.
  • Cochrane Evidence Synthesis Unit Germany/UK, Institute of General Practice, Centre for Health and Society, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Department of Public Health and Community Medicine, Tufts University School of Medicine, Medford, USA.
  • Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Department of Metabolism, Digestion and Reproduction - Faculty of Medicine, St Mary's Hospital, Clarence Wing, St Mary's Campus, London, UK.

ORCID-Profile: Carina Wagner

Zitieren

APA

Cryns, N., Schroer, J., Noel-Storr, A. H., Franco, J. V., Jahanfar, S., Messer, S., Zorger, A. M., Çolakkeskin, Ü., Widyaningsih, S. A., Mullins, E., Gibbs, K. D., Skoetz, N., & Wagner, C. (2026). Maternity versus non-maternity healthcare settings for the diagnosis of gestational diabetes or diabetes in pregnancy. Cochrane Database of Systematic Reviews, 2026(10). https://doi.org/10.1002/14651858.cd016295

Vancouver

Cryns N, Schroer J, Noel-Storr AH, Franco JV, Jahanfar S, Messer S, et al. Maternity versus non-maternity healthcare settings for the diagnosis of gestational diabetes or diabetes in pregnancy. Cochrane Database of Systematic Reviews. 2026;2026(10). doi:10.1002/14651858.cd016295

BibTeX
@article{Cryns2026,
  author = {Cryns, Nora and Schroer, Julia and Noel-Storr, Anna H and Franco, Juan Va and Jahanfar, Shayesteh and Messer, Sarah and Zorger, Ana-Mihaela and Çolakkeskin, Ünsal and Widyaningsih, Suci Ardini and Mullins, Edward and Gibbs, Karen D and Skoetz, Nicole and Wagner, Carina},
  title = {Maternity versus non-maternity healthcare settings for the diagnosis of gestational diabetes or diabetes in pregnancy},
  journal = {Cochrane Database of Systematic Reviews},
  year = {2026},
  volume = {2026},
  number = {10},
  doi = {10.1002/14651858.cd016295}
}
Kostenlos starten →